Anúncio
Anúncio
NTLA
Intellia Therapeutics, Inc
10.13
USDPatrocinado
+0.39
+4.04%
07 de jan., 16:00 UTC -5
Encerrado
Pré-Mercado
10.58
+0.45
+4.41%
Relatórios de Lucros NTLA
Rácio de surpresa positiva
NTLA separação 21 de 39 últimas estimativas.
54%
Próximo Relatório
Data do Próximo Relatório
25 de fev. de 2026
Estimate for Q4 25 (Revenue/ EPS)
$13.04M
/-$0.97
Mudanças implicadas de Q3 25 (Revenue/ EPS)
-5.36%
/+5.43%
Mudanças implicadas de Q4 24 (Revenue/ EPS)
+1.31%
/-23.62%
Intellia Therapeutics, Inc earnings per share and revenue
On 06 de nov. de 2025, NTLA reported earnings of -0.92 USD per share (EPS) for Q3 25, beating the estimate of -1.02 USD, resulting in a 9.97% surprise. Revenue reached 13.78 milhão, compared to an expected 15.49 milhão, with a -11.02% difference. The market reacted with a -22.73% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 23 analistas forecast an EPS of -0.97 USD, with revenue projected to reach 13.04 milhão USD, implying an aumentar of 5.43% EPS, and diminuir of -5.36% in Revenue from the last quarter.
FAQ
What were Intellia Therapeutics, Inc's earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, Intellia Therapeutics, Inc reported EPS of -$0.92, beating estimates by 9.97%, and revenue of $13.78M, -11.02% below expectations.
How did the market react to Intellia Therapeutics, Inc's Q3 2025 earnings?
The stock price moved down -22.73%, changed from $12.32 before the earnings release to $9.52 the day after.
When is Intellia Therapeutics, Inc expected to report next?
The next earning report is scheduled for 25 de fev. de 2026.
What are the forecasts for Intellia Therapeutics, Inc's next earnings report?
Based on 23
analistas, Intellia Therapeutics, Inc is expected to report EPS of -$0.97 and revenue of $13.04M for Q4 2025.
Which companies are reporting earnings today?
Verificar FXEmpire's Earnings Calendar for today's list of reporting companies.
Anúncio